Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ST7612AA1 is a novel potent and oral HDCA inhibitor that acts as an HIV-1 latency reactivator. ST7612AA1 showed significant antitumor activity at low concentrations in vitro and in vivo. ST7612AA1 has potential anticancer activity and can be used to study malaria.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 195.00 | |
5 mg | In stock | $ 483.00 | |
10 mg | In stock | $ 692.00 | |
25 mg | In stock | $ 1,080.00 | |
50 mg | In stock | $ 1,490.00 | |
100 mg | In stock | $ 1,970.00 | |
500 mg | In stock | $ 3,930.00 |
Description | ST7612AA1 is a novel potent and oral HDCA inhibitor that acts as an HIV-1 latency reactivator. ST7612AA1 showed significant antitumor activity at low concentrations in vitro and in vivo. ST7612AA1 has potential anticancer activity and can be used to study malaria. |
Molecular Weight | 405.51 |
Formula | C20H27N3O4S |
CAS No. | 1428535-92-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ST7612AA1 1428535-92-5 Microbiology/Virology Proteases/Proteasome HIV Protease MRT 92 MRT92. inhibitor inhibit